CHATHAM, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, presented data on ...
Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabolism, optimizing parent-drug exposure during sleep and decreasing levels of the persistent active metabolite The ...
TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass ...
NEW YORK - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced that its fibromyalgia treatment TONMYA demonstrated significant pain reduction compared to placebo in a Phase 3 clinical trial, ...
Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabolism, optimizing parent-drug exposure during sleep and decreasing levels of the persistent active metabolite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results